ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1UNH | UNITEDHEALTH GROUP INC | Healthcare | $363.01B | 25.68% |
2MCK | MCKESSON CORP | Healthcare | $124.35B | 8.80% |
3CVS | CVS HEALTH CORP | Healthcare | $114.88B | 8.13% |
4HCA | HCA HEALTHCARE INC | Healthcare | $104.58B | 7.40% |
5ELV | ELEVANCE HEALTH INC | Healthcare | $92.88B | 6.57% |
6CI | CIGNA GROUP | Healthcare | $78.07B | 5.52% |
7COR | CENCORA INC | Healthcare | $66.67B | 4.72% |
8CAH | CARDINAL HEALTH INC | Healthcare | $64.29B | 4.55% |
9HUM | HUMANA INC | Healthcare | $53.29B | 3.77% |
10MDLN | MEDLINE INC | Healthcare | $52.59B | 3.72% |
11GEHC | GE HEALTHCARE TECHNOLOGIES INC | Healthcare | $37.00B | 2.62% |
12CNC | CENTENE CORP | Healthcare | $34.79B | 2.46% |
13VTRS | VIATRIS INC | Healthcare | $23.70B | 1.68% |
14THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 1.61% |
15BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $14.22B | 1.01% |
16BAX | BAXTER INTERNATIONAL INC | Healthcare | $13.32B | 0.94% |
17UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $11.18B | 0.79% |
18MOH | MOLINA HEALTHCARE INC | Healthcare | $10.95B | 0.77% |
19DVA | DAVITA INC | Healthcare | $10.95B | 0.77% |
20OSCR | OSCAR HEALTH INC | Healthcare | $9.92B | 0.70% |
21HSIC | HENRY SCHEIN INC | Healthcare | $9.52B | 0.67% |
22PACS | PACS GROUP INC | Healthcare | $7.62B | 0.54% |
23BLCO | BAUSCH & LOMB CORP | Healthcare | $7.56B | 0.53% |
24OPCH | OPTION CARE HEALTH INC | Healthcare | $4.75B | 0.34% |
25NVST | ENVISTA HOLDINGS CORP | Healthcare | $3.95B | 0.28% |
26OGN | ORGANON & CO | Healthcare | $3.65B | 0.26% |
27ACHC | ACADIA HEALTHCARE COMPANY INC | Healthcare | $3.52B | 0.25% |
28SGRY | SURGERY PARTNERS INC | Healthcare | $3.48B | 0.25% |
29BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.22% |
30PRVA | PRIVIA HEALTH GROUP INC | Healthcare | $3.02B | 0.21% |
31AVAH | AVEANNA HEALTHCARE HOLDINGS INC | Healthcare | $2.67B | 0.19% |
32ARDT | ARDENT HEALTH INC | Healthcare | $2.49B | 0.18% |
33MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.45B | 0.17% |
34ADUS | ADDUS HOMECARE CORP | Healthcare | $2.31B | 0.16% |
35PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.16% |
36BKD | BROOKDALE SENIOR LIVING INC | Healthcare | $2.14B | 0.15% |
37FTRE | FORTREA HOLDINGS INC | Healthcare | $1.94B | 0.14% |
38TRLV | TRULIEVE CANNABIS CORP | Healthcare | $1.90B | 0.13% |
39AGL | AGILON HEALTH INC | Healthcare | $1.85B | 0.13% |
40XRAY | DENTSPLY SIRONA INC | Healthcare | $1.83B | 0.13% |
41ASTH | ASTRANA HEALTH INC | Healthcare | $1.77B | 0.13% |
42SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.12% |
43HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 0.12% |
44ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.11% |
45OMCL | OMNICELL INC | Healthcare | $1.61B | 0.11% |
46ENOV | ENOVIS CORP | Healthcare | $1.59B | 0.11% |
47TDOC | TELADOC HEALTH INC | Healthcare | $1.58B | 0.11% |
48ALHC | ALIGNMENT HEALTHCARE INC | Healthcare | $1.57B | 0.11% |
49CNMD | CONMED CORP | Healthcare | $1.50B | 0.11% |
50USPH | U S PHYSICAL THERAPY INC | Healthcare | $1.47B | 0.10% |
51AMN | AMN HEALTHCARE SERVICES INC | Healthcare | $1.44B | 0.10% |
52PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.10% |
53INNV | INNOVAGE HOLDING CORP | Healthcare | $1.28B | 0.09% |
54PNTG | PENNANT GROUP INC | Healthcare | $1.26B | 0.09% |
55AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.09% |
56TNDM | TANDEM DIABETES CARE INC | Healthcare | $1.22B | 0.09% |
57NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.08% |
58IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.08% |
59ATEC | ALPHATEC HOLDINGS INC | Healthcare | $1.10B | 0.08% |
60AHCO | ADAPTHEALTH CORP | Healthcare | $1.07B | 0.08% |
61BVS | BIOVENTUS INC | Healthcare | $915M | 0.06% |
62PHR | PHREESIA INC | Healthcare | $783M | 0.06% |
63COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $775M | 0.05% |
64VREX | VAREX IMAGING CORP | Healthcare | $769M | 0.05% |
65QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.05% |
66TCMD | TACTILE SYSTEMS TECHNOLOGY INC | Healthcare | $601M | 0.04% |
67MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.04% |
68ANGO | ANGIODYNAMICS INC | Healthcare | $504M | 0.04% |
69EOLS | EVOLUS INC | Healthcare | $475M | 0.03% |
70CTEV | CLARITEV CORP | Healthcare | $459M | 0.03% |
71ARVN | ARVINAS INC | Healthcare | $450M | 0.03% |
72EMBC | EMBECTA CORP | Healthcare | $364M | 0.03% |
73TMCI | TREACE MEDICAL CONCEPTS INC | Healthcare | $350M | 0.02% |
74VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.02% |
75EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.02% |
76OFIX | ORTHOFIX MEDICAL INC | Healthcare | $283M | 0.02% |
77AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.01% |
78ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.01% |
79OPRX | OPTIMIZERX CORP | Healthcare | $167M | 0.01% |
80INGN | INOGEN INC | Healthcare | $146M | 0.01% |
81BDSX | BIODESIX INC | Healthcare | $109M | 0.01% |
82PARK | PARK DENTAL PARTNERS INC | Healthcare | $101M | 0.01% |
83JYNT | JOINT CORP | Healthcare | $92M | 0.01% |
84GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.00% |
85XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.00% |
86POCI | PRECISION OPTICS CORPORATION INC | Healthcare | $55M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $1.41T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 98% toward Large, 37% toward Growth. +5% unclassified (19 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 86 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
Close to the line. The engine flags this verdict as one a routine data rebuild could flip. Read it as borderline rather than settled — the margin beside it is the whole story.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
1 verdict(s) sit within 1.0pp of their limit and can be flipped by a routine data rebuild; do not headline them, and always show the margin.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T032403 rates=20261113T032429
Measured on the 2026-11 formation date across 86 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators differ materially in value but agree on the verdict. Historical and Gaussian fund VaR differ by 26%; both still land on the same side of the 2x limit.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
There is no “before” to compare against — the predictor was already public when our data begins, so every month shown is out-of-sample relative to the original study.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 24.2% | -1.7% |
| 3 yearsp.a. | 7.4% | -22.0% |
| 5 yearsp.a. | 7.7% | -4.3% |
| 10 yearsp.a. | 11.1% | -2.1% |
| Since inceptionp.a. | 12.6% | -1.2% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 26.1% | -0.5% |
| 2025 | 1.7% | -27.0% |
| 2024 | -5.3% | -5.1% |
| 2023 | 2.3% | -27.5% |
| 2022 | 3.2% | 32.1% |
| 2021 | 30.8% | 106.3% |
| 2020 | 13.0% | -25.1% |
| 2019 | 20.5% | -21.1% |
| 2018 | 3.9% | 27.6% |
| 2017 | 20.5% | -26.0% |
| 2016 | -0.0% | 27.0% |
| 2015 | 7.8% | 3.8% |
| 2014 | 31.0% | -11.6% |
| 2013 | 47.5% | -0.3% |
| 2012 | 14.3% | -13.2% |
| 2011 | 14.6% | 10.7% |
| 2010 | 13.9% | 6.1% |
| 2009 | 31.7% | 12.9% |
| 2008 | -43.4% | -27.9% |
| 2007 | 17.6% | 17.7% |
| 2006 | 4.5% | 13.5% |
| 2005 | 31.2% | 16.8% |
| 2004 | 25.3% | 29.5% |
| 2003 | 35.6% | -6.1% |
| 2002 | -6.8% | 71.1% |
| 2001 | -0.6% | 15.2% |
| 2000 | 79.6% | -59.3% |
| 1999 | -10.3% | -36.1% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare Sales-to-Price Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a Sales-to-Price signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.